EXPAND: Brivaracetam Monotherapy in Childhood and Juvenile Absence Epilepsy

Phase 3, randomised, double-blind trial of brivaracetam in childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE) (8 arms), sponsored by UCB. Primary endpoint: Percentage of participants who met the criteria for absence seizure freedom within 4 days prior to or during the 24-hour ambulatory electroencephalogram (EEG). Started Jul 2021; status: completed.